Welcome to our dedicated page for SeaStar Medical Holding news (Ticker: ICU), a resource for investors and traders seeking the latest updates and insights on SeaStar Medical Holding stock.
SeaStar Medical Holding Corporation (Nasdaq: ICU) generates news that centers on its development and commercialization of therapies based on its patented Selective Cytopheretic Device (SCD) technology for critically ill patients. Company press releases highlight progress with its first commercial product, QUELIMMUNE (SCD-PED) therapy, which is approved by the U.S. Food and Drug Administration under a Humanitarian Device Exemption for life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients receiving Renal Replacement Therapy.
News updates frequently cover commercial adoption milestones for QUELIMMUNE, including new top-rated children’s hospitals that begin using the therapy and real-world outcomes reported through the SAVE Surveillance Registry. These releases often describe survival data, safety findings such as zero device-related adverse events, and registry enrollment updates that may influence the therapy’s market opportunity.
Investors following ICU news also see regular coverage of clinical development for SCD therapy in adult AKI and cardiovascular indications. This includes announcements related to the NEUTRALIZE-AKI pivotal trial in adults with AKI requiring continuous renal replacement therapy, DSMB recommendations, enrollment progress, and the initiation of studies such as the NEUTRALIZE-CRS trial in patients with acute chronic systolic heart failure and cardiorenal syndrome awaiting LVAD implantation.
Additional SeaStar Medical news items include regulatory and FDA interactions, such as Breakthrough Device Designations for multiple therapeutic indications and adjustments to post-approval surveillance requirements for QUELIMMUNE. Corporate updates, including reverse stock split actions, equity financings, financial results, and executive appointments, are also disclosed through press releases and associated SEC filings. For readers tracking ICU, the news stream provides insight into commercial traction, clinical trial status, regulatory milestones, and key corporate decisions that shape the company’s SCD-based therapy platform.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
SeaStar Medical Holding Corporation (Nasdaq: ICU) has activated its first clinical site, Good Samaritan Regional Medical Center in Oregon, for the pivotal NEUTRALIZE-AKI trial. This trial aims to evaluate the Selective Cytopheretic Device (SCD) therapy's effectiveness for critically ill adults suffering from acute kidney injury (AKI). The SCD, which recently received FDA Breakthrough Device Designation, targets inflammation to potentially reduce mortality and dialysis dependency. The trial anticipates enrolling up to 200 patients across 30 U.S. sites, with primary endpoints focusing on 90-day mortality and dialysis dependency. Previous studies indicated up to 50% reduction in mortality among patients using the SCD, highlighting its promise in improving patient outcomes.
SeaStar Medical Holding Corporation (Nasdaq: ICU) provides an update and financial results for 2022, focusing on its innovative Selective Cytopheretic Device (SCD) for hyperinflammation in acute kidney injury (AKI) patients. The FDA granted Breakthrough Device Designation to the SCD for adult AKI. A pivotal clinical trial, NEUTRALIZE-AKI, aims to enroll 200 patients across 30 sites, with results expected by mid-2025. The company reported a net loss of $23 million, or $2.80 per share, due to increased expenses. Cash reserves decreased to $47,000. The firm anticipates regulatory approval for pediatric AKI and has a partnership with Nuwellis to enhance market presence.